evipedia.ai
← Back

Ketamine for Health & Longevity

Evidence Review created on 09/12/2026 using AI4L / Opus 5

Also known as: Ketalar, Racemic Ketamine, (R,S)-Ketamine, Esketamine, Spravato, Arketamine, Ketanest

Motivation

Ketamine (Ketalar) is an anesthetic that has been used in operating rooms, emergency departments and battlefield medicine for more than fifty years. At a small fraction of the anesthetic dose it has been reported to lift severe low mood within hours rather than the weeks standard antidepressant medication requires, though its size is disputed. It blocks one of the brain’s main excitatory signalling receptors, and that block appears to trigger a short burst of new connections between nerve cells.

The compound was created in the early 1960s as a successor to an earlier anesthetic that caused severe agitation, and it spread quickly because it relieves pain without suppressing breathing. It later acquired a second life as a recreational drug, and a third as a clinic-administered treatment for low mood that has not responded to standard medication. A nasal spray version is now licensed in several countries.

This review examines what low-dose ketamine has been shown to do and not to do, how strong the evidence behind each claim is, which harms follow occasional as against frequent exposure, how the dosing schedules used by clinics differ from one another, and what can be measured before and during a course of treatment.

Benefits - Risks - Protocol - Conclusion

High-level overviews of ketamine from expert clinicians, researchers and long-form interviews that treat the compound in depth.

Nothing on foundmyfitness.com, chriskresser.com or lifeextension.com met the depth bar. FoundMyFitness carries only short news summaries of single ketamine studies; Chris Kresser and Life Extension mention the compound inside broader material on low mood or psychedelic-assisted therapy. Lifespan.io carries a database entry tracking one ketamine trial rather than an article discussing the compound, so it is excluded.

Grokipedia

Ketamine

A broad reference entry covering chemistry, anesthetic and analgesic use, the antidepressant literature, recreational patterns and the urinary and hepatobiliary harms reported in heavy users.

Examine

Ketamine

Examine’s entry frames ketamine as a fast-acting general anesthetic with pain-relieving, amnesic, anti-inflammatory, antidepressant and hallucinogenic properties, and links its curated feed of individual study summaries.

ConsumerLab

No ConsumerLab article on ketamine exists. ConsumerLab tests dietary supplements and does not typically cover prescription medications, and ketamine is a scheduled prescription drug, so its absence from the site is expected.

Systematic Reviews

Systematic reviews and meta-analyses covering both the claimed benefits of ketamine and its principal documented harms.

Mechanism of Action

Ketamine blocks the NMDA receptor (N-methyl-D-aspartate, the docking site for glutamate, the brain’s main excitatory messenger). At low doses it acts preferentially on inhibitory interneurons, releasing the brake on glutamate release; the resulting surge activates AMPA receptors (a second, faster glutamate receptor) and drives release of BDNF (brain-derived neurotrophic factor, a protein that supports the growth and survival of nerve cells). BDNF switches on mTOR (mechanistic target of rapamycin, a cellular growth-control hub), and within hours new synaptic connections appear in the prefrontal cortex, as Li and colleagues demonstrated in rodents.

Two rival accounts compete with this one. Zanos and colleagues reported that the metabolite (2R,6R)-hydroxynorketamine reproduces the antidepressant effect in animals without blocking NMDA receptors at all, which would make receptor blockade incidental. Williams and colleagues found that pretreatment with the opioid blocker naltrexone abolished the mood effect in humans, implicating mu-opioid receptors (the receptors morphine acts on) and so a dependence-liable pathway.

Pharmacologically, racemic ketamine is an equal mixture of two mirror-image forms, the S-form binding the NMDA receptor roughly four times more tightly. Distribution half-life is 10–15 minutes and elimination half-life 2–3 hours. Low plasma protein binding, near 12%, and high lipid solubility give fast, wide tissue distribution including brain. Metabolism is hepatic, chiefly by CYP2B6 and CYP3A4 with CYP2C9 minor (liver enzymes that break drugs down), to norketamine and then hydroxynorketamine, cleared renally. Selectivity is low: HCN1 channels (pacemaker ion channels in nerve cells), opioid receptors and monoamine transporters are also engaged.

Historical Context & Evolution

Ketamine was synthesised in 1962 by Calvin Stevens at Parke-Davis as compound CI-581, deliberately designed as a shorter-acting successor to phencyclidine, whose prolonged agitation had made it unusable. Edward Domino and Guenter Corssen gave it to human volunteers in 1964 and coined “dissociative anesthesia” to describe the detached, cataleptic (rigid and immobile) state it produced. United States approval as an anesthetic followed in 1970, and the drug went to Vietnam because it maintained blood pressure and breathing without the equipment an inhaled agent needs.

Elective surgical use in adults then declined, because a minority of patients woke with vivid and frightening imagery. That same property drove uptake as a recreational drug from the 1980s. In parallel, Soviet and later Russian psychiatrists used single high doses for alcohol dependence, and researchers at Yale used low doses to model psychosis, which is how its glutamate action came under systematic study.

The antidepressant finding emerged from that psychosis work: a seven-patient crossover study in 2000 and an eighteen-patient replication in 2006 both reported large, rapid improvement. The evidence has since moved in both directions. A nasal enantiomer gained approval in 2019; a 403-patient comparison against electroconvulsive therapy in 2023 found ketamine not inferior; and in the same year a trial that hid ketamine inside surgical anesthesia found no advantage over saline, reopening the question of how much of the observed benefit depends on the patient noticing the dose.

Expected Benefits

High 🟩 🟩 🟩

Rapid Reduction of Depressive Symptoms ⚠️ Conflicted

A single subanesthetic infusion lowers depression scores within hours in people whose symptoms have resisted standard medication, an effect attributed to the rapid synapse formation described above. Cochrane and an international pooled patient-level analysis of 17 trials both found a short-term advantage over placebo, larger in those with more prior failed medications. Certainty is contested: a trial masking ketamine inside surgical anesthesia found no advantage, and placebo response is unusually high. Net: the acute effect is real but smaller and less certain than open-label practice implies.

Magnitude: Response or remission at 24 hours versus placebo, odds ratio 3.94 (the multiple by which the odds of the outcome change; 95% confidence interval 1.54–10.10, the range in which the true value most likely lies) across seven trials; pooled effect size 0.58 at 24 hours and 0.38 at seven days.

Rapid Reduction of Suicidal Ideation

Ketamine reduces suicidal thinking faster than it reduces mood itself, often within a single day, and the effect is separable from the antidepressant response. A network meta-analysis of 14 studies and 1,380 participants found the reduction present on day one and still present at the end of repeated courses. The practical value is bridging: the interval during which standard treatment has not yet taken effect. Durability beyond a few weeks without repeat dosing has not been established, and the trials enrolled acutely ill patients rather than stable individuals.

Magnitude: Recovery from suicidal ideation within the first day, relative risk 10.02 (how many times more likely the outcome is; 95% confidence interval 4.24–23.68) versus comparator; still favourable at day 26, relative risk 4.29 (95% confidence interval 1.41–13.08).

Reduction of Post-Traumatic Stress Symptoms

Repeated infusions reduce the intrusive, avoidant and hyperarousal symptoms of chronic PTSD, plausibly by destabilising consolidated fear memories during the plasticity window. A randomised trial of six infusions against midazolam in 30 people with chronic PTSD, replicating an earlier single-dose trial, showed a clear separation from active placebo. Both trials were small and single-site, and benefit faded: among responders the median time to loss of response was under a month, so the result supports episodic courses rather than one-off treatment.

Magnitude: 11.88-point greater fall on the clinician-administered post-traumatic stress severity scale at two weeks (effect size 1.13, 95% confidence interval 0.36–1.91); 67% of the ketamine group responded versus 20% on midazolam.

Reduction of Anxiety Symptoms

Anxiety falls alongside, but not merely because of, the mood effect. A transdiagnostic meta-analysis of 14 randomised trials spanning mood disorders, anxiety disorders and chronic pain found reductions at every timepoint examined, and the correlation with depression improvement, while significant, left substantial variance unexplained. Peak dissociation did not predict the anxiolytic effect, which argues against the benefit being a simple by-product of the altered state. Risk of bias was high in 11 of the 14 trials, and follow-up rarely extended beyond two weeks.

Magnitude: Standardized mean difference (effect size in standard deviations) versus placebo of −1.17 under 12 hours, −0.44 at 24 hours and −0.40 at 7–14 days; all statistically significant.

Analgesia and Opioid Sparing Around Surgery

Added to standard anesthesia, ketamine reduces both postoperative pain scores and the amount of opioid required, an outcome with direct relevance to anyone facing elective surgery who wants to minimise opioid exposure. The Cochrane review of perioperative intravenous ketamine pooled 130 trials, and a meta-analysis of recovery quality found improved patient-reported recovery. The benefit is largest in operations expected to be painful and in opioid-tolerant patients; in low-pain procedures the added psychotomimetic (psychosis-like) effects may outweigh a marginal analgesic gain.

Magnitude: Opioid consumption over the first 24 hours fell by 8 mg morphine equivalents (95% confidence interval 6–9), 19% below the 42 mg used on placebo, across 65 trials; pain at rest at 24 hours fell 5 points on a 0–100 mm scale (95% confidence interval 4–7) across 82 trials; quality of recovery on day one improved by a standardized mean difference of 0.63.

Relief of Refractory Chronic Pain

Infusion courses produce analgesia in neuropathic pain, complex regional pain syndrome (a disabling limb pain condition with swelling and skin changes) and other refractory states, outlasting the drug’s presence in the body by days to weeks. A meta-analysis of seven randomised trials found benefit persisting up to two weeks after infusion, with a suggestion of dose-response. Six of the seven trials were at high risk of bias and the pooled sample was 211 patients, so the effect size is better established than its durability.

Magnitude: Mean difference of −1.83 points on a 0–10 pain scale (95% confidence interval −2.35 to −1.31) up to two weeks after infusion; responder rate 51.3% versus 19.4% on placebo (relative risk 2.43, 95% confidence interval 1.10–5.40).

Medium 🟩 🟩

Increased Abstinence in Alcohol Use Disorder

Three weekly infusions paired with psychological therapy increased days abstinent from alcohol six months later in a 96-participant phase 2 trial, with the largest gain in the group receiving both ketamine and mindfulness-based relapse prevention. The proposed mechanism is a plasticity window in which learned drinking associations become modifiable. Confidence intervals were wide, relapse rates did not differ between groups, and an earlier midazolam-controlled pilot was smaller still. The dose used, 0.8 mg/kg, exceeds the standard antidepressant dose.

Magnitude: 10.1 percentage points more days abstinent at six months versus placebo (95% confidence interval 1.1–19.0), rising to 15.9 points (95% confidence interval 3.8–28.1) for ketamine plus therapy versus saline plus education.

Sustained Symptom Control Under Maintenance Dosing

Gains from an induction course can be held for months by spacing subsequent doses to weekly or fortnightly, which is the pattern relevant to anyone considering ketamine as an ongoing rather than one-off intervention. A one-year open-label study of 802 patients on nasal esketamine found improvement maintained through the maintenance phase, and a systematic review of maintenance dosing across all routes reached the same conclusion. Neither body of evidence is placebo-controlled over that horizon, and the manufacturer, Janssen, designed, funded and staffed the esketamine study.

Magnitude: Depression rating scale score fell 16.4 points during the four-week induction phase and changed by 0.3 points across the following 48 weeks of maintenance; 24.9% of those entering maintenance completed the full year.

Low 🟩

Preservation of Cognitive Function During Treatment Courses

A systematic review of neurocognitive outcomes found no short-term cognitive impairment in patients treated for depression or PTSD, and possible gains in executive function, in contrast to the acute impairment seen in healthy volunteers. Evidence is uncontrolled and indirect, and no study extends past a single treatment course.

Magnitude: Direction is neutral-to-favourable for executive function in treated patients, holding across the reviewed studies at therapeutic doses. The reviewed literature reports no pooled outcome figure, as test batteries and timepoints were not harmonised.

Prevention of Postoperative Delirium ⚠️ Conflicted

Early single-centre work suggested ketamine given at induction protects older surgical patients from delirium (acute confusion). The 672-patient PODCAST trial found no difference and more hallucinations and nightmares at higher doses. Net: the best-powered trial refutes the benefit and signals possible harm.

Magnitude: Delirium incidence 19.45% with ketamine versus 19.82% with placebo (absolute difference 0.36%, 95% confidence interval −6.07 to 7.38).

Speculative 🟨

Reduction in Epigenetic Age Estimates

A 20-participant uncontrolled pilot reported lower estimated biological age on three methylation clocks after six infusions. No control group, no clinical endpoint; the sponsoring firms sell the tests and the treatment.

Anti-Inflammatory Signalling

Ketamine suppresses inflammatory messengers in cell and animal models, a pathway of interest given inflammation’s role in ageing. No human trial has measured inflammatory markers as a primary outcome, so the basis is mechanistic only.

Benefit-Modifying Factors

  • Metabolising-enzyme variants: Carriers of the CYP2B6*6 allele (a common variant of a drug-metabolising liver enzyme) clear ketamine roughly three times more slowly, so a standard weight-based dose delivers substantially higher exposure and, plausibly, a larger effect at the cost of more side effects.

  • BDNF Val66Met genotype: This common variant of the nerve-growth-factor gene impairs the activity-dependent release that ketamine’s mechanism depends on. A pharmacogenetic analysis examined it alongside CYP2B6 as predictors of response; findings across cohorts remain inconsistent.

  • Degree of prior treatment resistance: The pooled patient-level meta-analysis found the advantage over placebo was larger in trials requiring two or more failed medication trials for entry. Benefit is therefore concentrated in the refractory, not the mildly affected.

  • Baseline symptom severity and biomarkers: Higher baseline depression scores leave more room to move and predict larger absolute change. No blood biomarker reliably predicts response; baseline blood pressure and liver enzymes govern tolerability rather than efficacy.

  • Sex: A 99-participant dose-ranging trial found no difference in efficacy between women and men, nor between pre- and post-menopausal women. Women reported slightly more headache and nausea, differences that did not reach significance.

  • Pre-existing conditions: Comorbid anxiety does not blunt response. Active alcohol or benzodiazepine (a class of sedative, anxiety-reducing drugs) use tends to reduce it, as chronic gamma-aminobutyric acid (the brain’s main calming messenger) receptor tone opposes the glutamate surge on which the mechanism depends.

  • Age: Clearance falls with age independently of genotype, so older adults reach higher concentrations from the same weight-based dose. Response in later life is slower to appear but comparable in size once repeated dosing is allowed for.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Dissociation and Perceptual Disturbance

Detachment from body and surroundings, altered time perception and visual distortion begin within minutes and are dose-dependent. They are the drug’s defining effect rather than an incidental one, and the reference systematic review of side effects in depression found psychotomimetic effects reported more often with ketamine than placebo across trials. Severity is reduced by slower infusion and a quiet setting. Symptoms resolve within about 90 minutes of dosing and do not accumulate across a course, but they make driving unsafe for the remainder of the day.

Magnitude: Dissociation reported by 27.6% of 802 patients across a year of nasal esketamine dosing, transient and generally resolved within 1.5 hours after each dose.

Transient Elevation of Blood Pressure and Heart Rate

Ketamine produces a sympathetic surge that raises blood pressure and heart rate for roughly the duration of the infusion. A review of 684 infusions at a single academic centre found the rise small and clinically insignificant at 0.5 mg/kg over 40 minutes, with no infusion stopped for instability, although patients with existing hypertension peaked higher. No tolerance developed across six infusions. The concern is not the average patient but the outlier with untreated hypertension, aneurysmal disease or recent cardiac events, in whom the same surge is not benign.

Magnitude: Peak mean rise of 3.28 mmHg systolic and 3.17 mmHg diastolic at 30 minutes across 684 infusions, returning to baseline during post-infusion monitoring.

Nausea, Dizziness, Headache and Sedation

The commonest reasons people find dosing unpleasant are vestibular and gastrointestinal rather than psychological. In the year-long esketamine safety study these were the leading treatment-emergent events, most arising on dosing days, mild to moderate, and resolving the same day. Vomiting carries an aspiration risk (inhaling stomach contents into the lungs) if the stomach is not empty, which is why fasting is standard. Sedation resolves over two to four hours. None of these effects showed cumulative worsening over twelve months of repeated exposure.

Magnitude: Across 802 patients dosed for up to one year: dizziness 32.9%, nausea 25.1%, headache 24.9%; 9.5% discontinued for adverse events and 6.9% experienced a serious adverse event.

Ketamine-Associated Uropathy

Frequent heavy exposure damages the bladder lining, producing urinary frequency, urgency and suprapubic (lower abdominal) pain, and in advanced cases a contracted bladder and upper-tract obstruction. A meta-analysis of 45 studies and 4,921 patients found the syndrome dominated by lower-tract symptoms with reduced functional capacity, and abstinence necessary for any improvement. The population studied is recreational users taking grams daily, not patients on supervised courses, but the dose-duration threshold at which risk begins has never been defined, which is the central unknown for long-term use.

Magnitude: Among affected users, pooled prevalence of urinary frequency 77.1%, urgency 69.9%, suprapubic pain 60.4% and hydronephrosis (urine backing up and swelling the kidney) 30.2%; pooled functional bladder capacity 95 mL against a normal 400–600 mL.

Dependence, Craving and Escalating Use

Ketamine is self-administered by animals and is a scheduled controlled substance. A one-year longitudinal study of 150 people found frequent users increased intake over the year and showed a dose-response relationship with delusional symptoms, and the naltrexone-blockade finding supplies a mechanistic route through mu-opioid receptors. Supervised, spaced clinical dosing has not shown this pattern, but take-home oral and sublingual formulations remove the structural barrier that supervision provides.

Magnitude: In the longitudinal cohort, frequent users escalated intake across 12 months, with delusional symptom scores graded by use frequency; both frequent and abstinent former users showed rising depression scores over the same period. The literature reports no outcome figure, as the cohort published correlations with use frequency rather than a rate of dependence.

Medium 🟥 🟥

Cognitive Impairment with Frequent Heavy Use ⚠️ Conflicted

Frequent recreational users declined over a year on spatial working memory and pattern recognition, in proportion to escalating intake. A systematic review of therapeutic dosing found no such impairment in patients, and possible executive gains. Net: the deficit tracks cumulative heavy exposure, not supervised courses, but no study has tested multi-year maintenance dosing, which sits between the two.

Magnitude: In frequent users, increasing use across 12 months correlated with declining spatial working memory and pattern recognition memory; therapeutic-dose studies report no equivalent decline. The literature reports no pooled outcome figure, as the cohort published correlations only and the therapeutic-dose review did not harmonise its test batteries.

Hepatobiliary Injury and Cholangiopathy

Heavy chronic exposure causes cholangiopathy (injury to the bile ducts), producing a cholestatic (obstructed bile flow) pattern of liver blood tests and, on imaging, dilated bile ducts without obstruction. A cross-sectional study of 297 chronic users found bile duct injury in every biopsied case and bridging fibrosis (advanced liver scarring) in two despite young age. The pattern is usually reversible on abstinence. As with the bladder, the exposure studied far exceeds clinical dosing, and no threshold below which the risk vanishes has been established.

Magnitude: Prevalence of significant liver injury 9.8% among 297 chronic users screened, all cholestatic; bile duct injury in 7 of 7 biopsies and common bile duct dilatation in 3 of 6 imaged.

Hallucinations and Nightmares at Higher Doses

Above the antidepressant range the detachment tips into frankly unpleasant experience. In the 672-patient surgical trial, hallucinations and nightmares rose with dose across placebo, 0.5 mg/kg and 1.0 mg/kg arms, and the authors concluded the drug might cause harm by inducing negative experiences. This is the historical “emergence reaction” (disturbing imagery on waking) that pushed ketamine out of routine adult anesthesia, and it is the principal argument against dose escalation when a standard dose underperforms.

Magnitude: Dose-graded increase in postoperative hallucinations and nightmares across three randomised arms in 672 older surgical patients; no corresponding increase in cardiovascular, renal, infectious, gastrointestinal or bleeding events. The literature reports no outcome figure, as the trial published only the significance of the dose trend.

Low 🟥

Loss of Response Across Repeated Courses

Diminishing returns from successive courses are reported in case series but were judged uncommon in the systematic review of maintenance dosing, which found tachyphylaxis (fading response to a repeated drug), cognitive impairment and addiction all infrequent. Evidence is uncontrolled and follow-up is short.

Magnitude: Direction is toward infrequent loss of response under spaced maintenance dosing. The reviewed studies report no pooled incidence figure, as none was designed to measure tachyphylaxis prospectively.

Raised Intracranial and Intraocular Pressure ⚠️ Conflicted

Older anesthetic literature attributed rises in skull and eye pressure to ketamine; a systematic review in traumatic brain injury found no significant intracranial-pressure rise, though hypotension episodes were more frequent. The data are indirect, mattering only where such disease exists. Net: the older pressure signal does not survive controlled testing.

Magnitude: No significant rise in intracranial pressure where baseline pressure was below 20 mmHg, relative risk 0.67 (95% confidence interval 0.45–1.01), pooled across 15 studies; hypotension episodes were more frequent, relative risk 1.47 (95% confidence interval 1.22–1.78).

Speculative 🟨

Long-Term Structural Brain Change from Years of Exposure

Repeated high-dose exposure produces neuronal changes in rodents and primates. No human imaging study has followed maintenance-dosed patients for years, so the basis is animal work and isolated reports from heavy recreational users.

Risk-Modifying Factors

  • CYP2B6*6 carriage: Slower clearance raises peak concentration from an unchanged weight-based dose, and the chronic-pain study that quantified it found lower clearance in those who experienced adverse effects.

  • Baseline blood pressure and liver enzymes: Existing hypertension produces higher peaks during infusion. Raised bile-duct enzymes at baseline remove the ability to detect drug-related cholestatic injury against a moving background.

  • Sex: The 99-participant dose-ranging trial found no significant difference in adverse event frequency between women and men; women reported numerically more headache and nausea. Bladder injury series are male-predominant, reflecting use patterns rather than biology.

  • Pre-existing conditions: Psychotic disorders, untreated hypertension, aneurysmal vascular disease, active substance use disorder and prior ketamine cystitis (bladder inflammation) each raise risk sharply. Hepatic impairment slows clearance and prolongs every dose-related effect.

  • Age: Clearance declines with age, so older adults reach higher concentrations and stay dissociated longer. Falls during the recovery window and orthostatic hypotension (a drop in blood pressure on standing) are the practical hazards.

Key Interactions & Contraindications

  • Benzodiazepines (diazepam, lorazepam, clonazepam): Caution. Concurrent use blunts the antidepressant response and deepens sedation. Mitigation is separation — holding the evening dose before a session where clinically safe; abrupt discontinuation to accommodate dosing is unsafe.

  • Opioid receptor antagonists (naltrexone, naloxone, nalmefene): Caution. Pretreatment abolished the mood effect without affecting dissociation. Anyone on naltrexone for alcohol or opioid use should expect the antidepressant benefit to be absent.

  • Monoamine oxidase inhibitors (tranylcypromine, phenelzine, selegiline — an older antidepressant class): Caution bordering on contraindication. Additive sympathetic stimulation risks hypertensive crisis (a dangerous blood pressure spike). Requires blood pressure monitoring throughout and a reduced ketamine dose.

  • CYP3A4 and CYP2B6 inhibitors (clarithromycin, ritonavir, ketoconazole, grapefruit juice): Monitor. Reduced clearance raises exposure and prolongs dissociation. Mitigation is a 25–50% dose reduction or separation of the interacting agent from the dosing day.

  • CYP3A4 inducers (rifampin, carbamazepine, phenytoin, efavirenz): Monitor. Accelerated clearance lowers exposure and can render a standard dose ineffective. Mitigation is upward dose titration under supervision rather than adding a second agent.

  • Stimulants and sympathomimetics (amphetamine, methylphenidate, pseudoephedrine, phenylephrine — agents that mimic adrenaline): Caution. Additive rise in blood pressure and heart rate. Mitigation is withholding them on dosing days, with blood pressure checked beforehand.

  • Theophylline and aminophylline: Caution. The combination lowers seizure threshold. Mitigation is avoiding co-administration on dosing days where an alternative bronchodilator exists.

  • Thyroid hormone replacement (levothyroxine, liothyronine): Monitor. The ketamine label notes hypertension and tachycardia when thyroid hormone is co-administered. Mitigation is confirming thyroid levels are normal before a course.

  • Alcohol and other sedatives (diphenhydramine, zolpidem, cannabis): Caution. Additive sedation and respiratory depression; alcohol also compounds hepatic and bladder injury. Mitigation is abstinence on dosing days and for 24 hours afterwards.

  • St. John’s wort: Monitor. A potent CYP3A4 inducer, it lowers ketamine exposure unpredictably. Mitigation is discontinuation at least two weeks before a course rather than dose adjustment.

  • Supplements with additive blood-pressure effects (caffeine, yohimbine, synephrine, liquorice root, high-dose tyrosine): Caution. Each amplifies the sympathetic surge. Mitigation is omission for 12 hours before dosing, resumed afterwards.

  • Sedating supplements (valerian, kava, melatonin, high-dose magnesium, gamma-aminobutyric acid precursors): Caution. Additive sedation prolongs the recovery window. Mitigation is shifting them to evening use on non-dosing days.

  • Other interventions: Psychotherapy within 24 hours — no restriction; it adds to the effect rather than interacting adversely. Electroconvulsive therapy — caution; concurrent use compounds memory loss, so the two are given as alternatives rather than together.

Populations who should avoid Ketamine:

  • Uncontrolled hypertension, defined as resting blood pressure at or above 180/110 mmHg
  • Aneurysmal vascular disease, including thoracic, abdominal and intracranial aneurysm, and arteriovenous malformation (a tangle of abnormal blood vessels)
  • Myocardial infarction within the preceding 6 weeks, or unstable angina
  • Prior intracerebral haemorrhage of any age
  • Active psychosis, schizophrenia or a history of ketamine-precipitated psychotic episode
  • Severe hepatic impairment, Child-Pugh Class C (the most advanced grade of liver failure)
  • Pre-existing ketamine-associated cystitis or unexplained blood in the urine
  • Active moderate-to-severe substance use disorder involving dissociatives, alcohol or opioids
  • Pregnancy and breastfeeding
  • Raised intracranial pressure from any cause

Risk Mitigation Strategies

  • Standard dosing without escalation: Holding 0.5 mg/kg intravenously over 40 minutes, rather than escalating when a session underperforms, limits the dissociation, hallucinations and nightmares that rose dose-dependently in the surgical trial.

  • Pre-dose blood pressure gate: Deferring any session at a resting blood pressure above 160/100 mmHg, and rechecking every 10 minutes until baseline returns, prevents the sympathetic surge from compounding untreated hypertension.

  • Fasting before dosing: No solid food for 6 hours and no liquids for 2 hours removes the aspiration risk that vomiting during dissociation would otherwise create.

  • Capped cumulative exposure: Limiting maintenance to one dose every 1–4 weeks after induction, rather than weekly indefinitely, keeps lifetime exposure far below the daily-gram patterns associated with bladder and bile-duct injury.

  • Quarterly urine dipstick: Testing for blood, protein and leucocytes every 3 months, with symptom review for urgency and frequency, catches ketamine-associated uropathy while it is still reversible on abstinence.

  • Liver enzyme panel every 6 months: Tracking the bile-duct enzymes detects the cholestatic injury pattern reported with heavy use before fibrosis develops.

  • Supervised administration and no self-titration: Clinic or observed dosing, with no take-home supply beyond a single scheduled dose, removes the access pattern that drives escalation and dependence.

  • No driving or machinery for 24 hours: A fixed rule rather than a self-assessment prevents accidents during residual sedation and perceptual disturbance.

  • Benzodiazepine review before starting: Tapering or timing benzodiazepines away from dosing days, under prescriber supervision, avoids both the blunted response and the additive sedation.

Therapeutic Protocol

  • Standard induction course: 0.5 mg/kg of racemic ketamine infused intravenously over 40 minutes, twice weekly for three weeks — six infusions — is the regimen used in the large comparative trials and the most widely replicated schedule.

  • Maintenance phase: Responders step down to one infusion weekly, then every 2–4 weeks, titrated to the interval at which benefit is maintained. Indefinite weekly dosing is generally avoided in favour of the longest workable interval.

  • Nasal esketamine alternative: 56 mg or 84 mg twice weekly for four weeks, then weekly or fortnightly, self-administered under observation. This route is licensed and insurer-covered where the injectable is not.

  • Intramuscular and subcutaneous routes: 0.5–1.0 mg/kg intramuscularly gives roughly 93% bioavailability with no line required, favoured in psychotherapy-integrated practice; subcutaneous dosing is used similarly in palliative settings.

  • Sublingual and oral formulations: Troches of 50–300 mg every 3–7 days are used in at-home programmes. Bioavailability is low and variable — near 30% sublingually, under 25% orally — so equivalence to infusion doses cannot be assumed.

  • Chronic pain regimens: Lower and longer, typically 0.35–0.5 mg/kg over 30–120 minutes, with multi-day continuous protocols reserved for complex regional pain syndrome in specialist centres.

  • Competing approaches: The psychiatry-led model treats ketamine as a pharmacological agent given in a quiet room; the ketamine-assisted psychotherapy model treats the session as the therapeutic event. Neither has beaten the other in a head-to-head trial.

  • Who popularised each: The infusion model traces to John Krystal and Gerard Sanacora at Yale and Carlos Zarate at the National Institute of Mental Health; the psychotherapy-integrated model to Phil Wolfson; nasal esketamine to Janssen.

  • Best time of day: Morning to early afternoon. The drug is alerting for several hours after the dissociative phase ends, and later sessions displace sleep onset on the dosing night.

  • Half-life and dose splitting: Elimination half-life is 2–3 hours, so the drug is cleared well before the next session. Doses are given as a single slow administration, not split, because the plasticity trigger depends on reaching a threshold concentration.

  • Pharmacogenetic considerations: CYP2B6*6 carriers clear the drug roughly three times more slowly and merit a reduced starting dose; BDNF Val66Met carriers may respond less, though evidence is not consistent enough to guide dosing.

  • Sex-based differences: Efficacy and tolerability did not differ between women and men, or by menopausal status, in the dose-ranging trial, so no sex-specific dose adjustment is supported.

  • Age-related adjustment: Clearance falls with age. Starting at 0.3–0.4 mg/kg in those over 65 and extending the observation window reflects both slower clearance and the fall risk during recovery.

  • Baseline biomarkers as dosing inputs: Resting blood pressure and liver enzymes determine whether a standard dose is appropriate; neither predicts efficacy, and no biomarker currently guides dose selection upward.

  • Pre-existing conditions: Comorbid anxiety does not alter dosing. Chronic benzodiazepine or heavy alcohol use blunts response, and hepatic impairment requires dose reduction proportional to the degree of impairment.

Discontinuation & Cycling

  • Not a lifelong medication: Ketamine is given as discrete courses with defined endpoints, not as continuous daily therapy. The default is to stop after induction and re-treat on relapse rather than dose indefinitely.

  • No physiological withdrawal syndrome: Stopping after a supervised course produces no autonomic withdrawal. Heavy chronic users report craving, low mood and, in the longitudinal cohort, rising depression scores after stopping.

  • Relapse rather than withdrawal: The usual event after stopping is return of the original symptoms over weeks. Among post-traumatic stress responders the median time to loss of response was under a month.

  • Tapering by interval, not by dose: Discontinuation is achieved by lengthening the gap between sessions — weekly to fortnightly to monthly — rather than reducing the amount given, since sub-threshold doses lose the effect entirely.

  • Cycling is the standard pattern: Spacing doses is done to limit cumulative bladder and bile-duct exposure and to preserve response, not because tolerance is established. Loss of response across courses appears uncommon.

  • Restarting after a break: Repeat induction courses are generally shorter than the first, commonly two to four sessions, with the same monitoring applied from the outset.

Sourcing and Quality

  • Pharmaceutical-grade product only: Ketamine hydrochloride injection is a regulated sterile product. Illicit powder is frequently adulterated and of unknown concentration, and accounts for essentially all reported bladder and bile-duct injury.

  • Licensed compounders for non-injectable forms: Sublingual troches and nasal solutions are compounded, not manufactured to marketing-authorisation standards. Facilities registered as outsourcing facilities apply batch potency and sterility testing that smaller compounders may not.

  • What to look for: A certificate of analysis with assayed potency for the specific batch, named excipients, a defined beyond-use date, and a pharmacy licence verifiable with the state board. Absence of any of these is disqualifying.

  • Third-party testing is not routine: Unlike supplements, compounded ketamine is rarely subject to independent verification. Where a programme cannot produce batch analysis, potency is unverified and dose equivalence to trial regimens is unsupported.

  • Named sources: The reference injectable products are Ketalar and its generic equivalents; the licensed nasal esketamine product is Spravato, dispensed only through certified pharmacies under a Risk Evaluation and Mitigation Strategy (a mandated safety programme).

  • Storage and handling: Solutions are stored at controlled room temperature away from light. Compounded troches degrade faster than injectables and are discarded at the stated beyond-use date rather than stockpiled.

Practical Considerations

  • Time to effect: Mood and suicidal-ideation changes appear within 40 minutes to 24 hours of the first dose. Pain and post-traumatic stress responses build over a course of four to six sessions rather than appearing after one.

  • Duration of benefit: A single dose typically holds for three to seven days; a full induction course for weeks to a couple of months. Planning for maintenance from the outset avoids an abrupt return of symptoms.

  • Common pitfall — escalating instead of spacing: When benefit fades, raising the dose increases hallucinations and nightmares without reliably restoring effect. Shortening the interval within safe cumulative limits is the better lever.

  • Common pitfall — treating it as a standalone: Trials pairing infusions with structured therapy produced the largest and most durable effects. Dosing without any behavioural component discards much of the demonstrated benefit.

  • Common pitfall — unsupervised at-home use: Take-home formulations remove observation at precisely the point where blood pressure, vomiting and escalation need watching, and no controlled trial has validated the model.

  • Regulatory status: Injectable ketamine is a Schedule III controlled substance in the United States and is used off-label for every indication in this review. Nasal esketamine is licensed for treatment-resistant depression under a restricted distribution programme.

  • Cost and access: A clinic infusion course commonly costs several thousand dollars and is rarely reimbursed, while licensed nasal esketamine is covered. Generic ketamine costs a few dollars a vial, so the price gap reflects delivery and licensing, not the drug.

  • Structural bias from payer incentives: Because insurers reimburse licensed nasal esketamine but rarely the far cheaper generic infusion, payers and manufacturers both favour the branded form, which plausibly skews guideline formation and research funding away from generic ketamine.

Interaction with Foundational Habits

  • Sleep: Direct and bidirectional. Ketamine increases slow-wave sleep and slow-wave activity on the night after dosing, an effect tied to the same nerve-growth-factor signalling that carries the mood response. Dosing after mid-afternoon delays sleep onset because the alerting phase outlasts the dissociative one; scheduling sessions before 14:00 preserves the sleep benefit without the delay.

  • Nutrition: Indirect, mainly a safety constraint. No solid food for 6 hours and no liquids for 2 hours before dosing prevents vomiting and aspiration during dissociation. Grapefruit juice inhibits the enzyme clearing the drug and is avoided for 48 hours either side. No diet alters the response, and no nutrient depletion is described.

  • Exercise: Potentiating in principle, restricted in practice. Both exercise and ketamine raise nerve-growth-factor signalling, so regular training plausibly adds to the plasticity effect on non-dosing days. Strenuous exercise on a dosing day is avoided: it compounds the blood-pressure rise, and impaired coordination during the recovery window makes loaded or technical training unsafe.

  • Stress management: Direct and synergistic. The plasticity window appears to make learned associations modifiable, which is why pairing sessions with structured therapy produced the largest effects in the alcohol trial. Ketamine acutely raises cortisol and prolactin; breathwork or meditation reduces anticipatory anxiety before a first session.

Monitoring Protocol & Defining Success

Before a first dose, three things are established: cardiovascular fitness for the sympathetic surge, a liver and urinary baseline against which later injury can be detected, and a quantified symptom score that makes response measurable rather than impressionistic. Blood pressure and heart rate are taken seated after five minutes of rest, and a full liver panel, kidney function and urine dipstick are drawn within two weeks of starting. A validated self-rated symptom questionnaire is completed on the same day.

Thereafter, blood pressure and heart rate are measured every 10 minutes during each session and until values return to baseline. Symptom scores are repeated at 24 hours after the first dose, then weekly through induction. Urine dipstick and liver enzymes are repeated at 3 months, then every 6 months for as long as dosing continues, and immediately if urinary symptoms appear.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Resting blood pressure Below 120/80 mmHg before each session Ketamine raises it transiently Seated, after 5 minutes’ rest, before dosing and every 10 minutes during; defer the session above 160/100 mmHg. Conventional practice accepts up to 140/90 mmHg, well above this target
Resting heart rate 50–70 bpm Same sympathetic surge raises it Measure with blood pressure; caffeine within 12 hours exaggerates the rise. Conventional reference ranges run to 100 bpm, well above this target
ALT 10–26 U/L in men, 8–22 U/L in women Detects liver cell injury reported with heavy use ALT is alanine aminotransferase, an enzyme released when liver cells are damaged. No fasting needed. Conventional laboratory ranges extend to 40–55 U/L, far above the functional target
ALP and GGT ALP 50–100 U/L; GGT below 20 U/L in men, below 15 U/L in women Cholestatic bile-duct injury is the pattern seen with ketamine ALP is alkaline phosphatase and GGT is gamma-glutamyl transferase, both raised when bile flow is obstructed. A rising GGT with a normal ALT points specifically at the bile ducts. Conventional laboratory ranges extend to roughly 130 U/L for ALP and 55–70 U/L for GGT, far above these targets
Total bilirubin 0.3–1.0 mg/dL Completes the cholestatic picture alongside the bile-duct enzymes Draw fasting with the liver panel; transient rises after prolonged fasting are common and not drug-related
Urine dipstick: blood, protein, leucocytes Negative for all three Earliest detectable sign of bladder lining injury Mid-stream sample, not during menstruation. Pair with a symptom review for urgency, frequency and suprapubic pain
Serum creatinine with eGFR eGFR above 90 mL/min/1.73 m² Upper-tract obstruction follows advanced bladder disease eGFR is estimated glomerular filtration rate, a calculated measure of kidney filtering capacity. Fasting preferred; avoid creatine supplements for 72 hours beforehand as they inflate creatinine. Conventional practice treats anything above 60 mL/min/1.73 m² as normal, well below this target
PHQ-9 score Below 5, or at least a 50% fall from the individual’s own baseline Defines response and remission objectively PHQ-9 is the Patient Health Questionnaire-9, a nine-item self-rated depression scale. Complete at the same time of day, before rather than after a session
CADSS score No established target; track the peak against the individual’s own first session Quantifies dissociation so escalation can be detected CADSS is the Clinician-Administered Dissociative States Scale. Administered at peak effect, roughly 40 minutes in. A rising peak at an unchanged dose warrants review

Qualitative markers worth tracking alongside the numbers:

  • Sleep quality and total sleep time on the night after dosing compared with a typical night
  • Energy and motivation on days 2–5 after a session, which is when the mood effect is usually clearest
  • Cognitive clarity, particularly word-finding and short-term recall, tracked for decline across a course
  • Duration of the interval before symptoms return, which is the single most useful guide to maintenance spacing
  • Anhedonia (loss of pleasure) specifically — whether previously enjoyable activities regain their pull — since it often shifts before overall mood scores do
  • Urinary urgency, frequency or discomfort, reported immediately rather than at the next scheduled review

Emerging Research

  • Head-to-head comparison of the two licensed forms: NCT06713616, a Yale-led phase 3 equivalence study of 400 participants funded by the Patient-Centered Outcomes Research Institute, compares nasal esketamine against generic intravenous ketamine on self-reported effectiveness — the comparison no manufacturer has an incentive to run.

  • Ketamine as a plasticity adjunct to exposure therapy: NCT05737693, a 350-participant phase 2 trial, tests whether ketamine plus exposure therapy outperforms midazolam plus exposure therapy for post-traumatic stress, with amygdala activation to trauma memory as a mechanistic endpoint.

  • Testing the opioid mechanism directly: NCT05940324, a 150-participant Stanford phase 2 trial in obsessive-compulsive disorder, examines whether mu-opioid receptors mediate ketamine’s rapid effects. A positive result would reframe the dependence risk for long-term use.

  • A metabolite without the dissociation: NCT06511908, a 50-participant phase 2 National Institute of Mental Health trial of (2R,6R)-hydroxynorketamine, tests whether the antidepressant effect survives removal of the psychoactive experience — the decisive experiment for the competing mechanistic accounts.

  • Preventing chronic pain after surgery: NCT05037123, a 765-participant phase 3 trial at NYU Langone Health, tests whether intraoperative ketamine reduces pain severity months after surgery, an endpoint earlier meta-analyses left unresolved.

  • The masking problem may shrink the effect: Lii et al., 2023 found no advantage over saline when ketamine was hidden inside surgical anesthesia, and Matsingos et al., 2024 documented an unusually high placebo response. Replication in larger masked samples could substantially reduce the estimated benefit.

  • Biological ageing as an outcome: Dawson et al., 2025 reported lower methylation-clock age after six infusions in 20 patients. The work was conducted by companies selling both the testing and the treatment, and needs controlled replication by an independent group.

  • Deprescribing and durability: No trial has yet followed maintenance-dosed patients for the multi-year horizon a longevity-oriented user would occupy, leaving cumulative bladder, bile-duct and cognitive outcomes at that timescale unmeasured.

Conclusion

Ketamine is an old anesthetic with a genuinely unusual property: at low doses it changes mood, suicidal thinking and pain within hours rather than weeks, and it does so in people for whom standard treatments have already failed. That much is supported by repeated controlled trials. What remains unsettled is how large the effect really is once the obvious experience of taking the drug is properly hidden from participants, because the one trial that managed to hide it found nothing, and the placebo response in this field is unusually strong.

The harms divide cleanly by pattern of use. Supervised, spaced courses produce transient detachment, a brief rise in blood pressure, nausea and dizziness, none of which accumulated over a year of dosing. Frequent heavy use damages the bladder and bile ducts, erodes memory and escalates. The dose and duration at which the first pattern turns into the second has never been established, and that gap is the central unknown for anyone contemplating years rather than weeks of use.

Much of the strongest long-term evidence comes from the company selling the licensed nasal form, from telehealth firms selling at-home courses, and from testing companies selling the ageing biomarkers, each with a direct financial stake in a favourable reading. The signal survives that scrutiny for short courses in illness that has not responded to standard treatment; for indefinite maintenance in healthy, high-functioning people, it has simply not been tested.

Top - Benefits - Risks - Protocol